MinichMacGregor Wealth Management LLC Buys 4,318 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

MinichMacGregor Wealth Management LLC lifted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 5.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 83,718 shares of the medical equipment provider’s stock after buying an additional 4,318 shares during the quarter. MinichMacGregor Wealth Management LLC’s holdings in Lantheus were worth $7,489,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Envestnet Asset Management Inc. boosted its holdings in shares of Lantheus by 0.3% during the 2nd quarter. Envestnet Asset Management Inc. now owns 111,498 shares of the medical equipment provider’s stock valued at $8,952,000 after buying an additional 356 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Lantheus by 1.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock worth $99,525,000 after purchasing an additional 19,071 shares during the period. Mercer Global Advisors Inc. ADV bought a new position in shares of Lantheus during the second quarter valued at approximately $209,000. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Lantheus by 20.6% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 7,025 shares of the medical equipment provider’s stock valued at $564,000 after purchasing an additional 1,202 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Lantheus in the 2nd quarter worth approximately $313,000. 99.06% of the stock is owned by institutional investors.

Lantheus Stock Performance

LNTH opened at $95.39 on Thursday. The company’s 50-day simple moving average is $90.36 and its two-hundred day simple moving average is $100.29. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The stock has a market capitalization of $6.63 billion, a P/E ratio of 15.87 and a beta of 0.46.

Analyst Ratings Changes

A number of brokerages have issued reports on LNTH. The Goldman Sachs Group assumed coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. JMP Securities reissued a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $120.00 target price (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $131.86.

Insider Activity at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.50% of the stock is owned by insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.